KR EN
background pattern

Precision-designed
kinase inhibitors
that reach where others can't, including the brain.

 
PIPELINE

A precisely crafted pipeline, accelerating the pace of drug discovery.

With hundreds of thousands of experimental data points and robust target validation, Voronoi rapidly identifies and optimizes promising drug candidates. Discover how innovation unfolds in our pipeline.

 
Publications

Science with purpose.

From design to clinic delivering targeted therapies that matter. Explore our research and breakthroughs.

background pattern
OUR Approach

VORONOMICS-Based Drug Design

VORONOMICS, a proprietary platform, revolutionizes the drug development process, enabling the rapid discovery of development candidates with exquisite selectivity and brain penetration that are unprecedent.

Latest Highlights

ESMO Congress 2026 (ESMO2026)

ESMO Congress 2026

Voronoi is excited to participate in the ESMO 2026

  • calendar icon Date & Time: October 23 - 27, 2026
  • location icon Location: Madrid, Spain

Latest News

  • 2026.10.27
Voronoi Unveils Clinical Results of EGFR-Mutant Lung Cancer Drug VRN11 at ESMO

Voronoi (310210) announced on the 27th that it presented Phase 1 clinical results of VRN11, its treatment for EGFR-mutant non-small cell lung cancer, as a poster at the European Society for Medical Oncology (ESMO 2026) held in Madrid, Spain.

  • 2026.10.26
Voronoi Presents Phase 1 Results of HER2-Targeted Anticancer Drug ‘VRN10’ at ESMO 2026

Voronoi (310210) announced on the 26th that it presented Phase 1 clinical results of VRN10, its HER2-targeted anticancer drug, as a poster at the ESMO Congress 2026 (European Society for Medical Oncology annual meeting), held in Madrid, Spain, from October 23 to 27.

View More